Parameters | Values | Sources |
---|---|---|
Proportion of patients assigned to each risk group | ||
Adjuvant! Online low risk | 52.99 % | Paulden et al. (2013) |
21-Gene assay low risk | 32.34 % | |
21-Gene assay int. risk | 12.57 % | |
21-Gene assay high risk | 8.08 % | |
Adjuvant! Online int. risk | 18.71 % | |
21-Gene assay low risk | 8.53 % | |
21-Gene assay int. risk | 3.59 % | |
21-Gene assay high risk | 6.59 % | |
Adjuvant! Online high risk | 28.29 % | |
21-Gene assay low risk | 9.73 % | |
21-Gene assay int. risk | 6.14 % | |
21-Gene assay high risk | 12.43 % | |
Proportion of patients in each risk group provided adjuvant chemotherapya | ||
Adjuvant! Online low risk | 0 % | |
21-Gene assay low risk | 0 % | |
21-Gene assay int. risk | 17.62 % | |
21-Gene assay high risk | 63.44 % | |
Adjuvant! Online int. risk | 55.06 % | |
21-Gene assay low riska | 13.73 (T1, base case)/(0 % T2, SA) | |
21-Gene assay int. risk | 36.56 % | |
21-Gene assay high risk | 98.61 % | |
Adjuvant! Online high risk | 57.57 % | |
21-Gene assay low risk | 13.72 % | |
21-Gene assay int. risk | 36.65 % | |
21-Gene assay high risk | 99.73 % | |
Risk of hospital visit due to toxicity | 17.04 % | Tilak Financial Department and Cost Data Report (2012) |
Cause of hospital visits due to toxicity | ||
Neutropenia/fever/infections | 53.56 % | Medical University Innsbruck (2012) |
Pain & pain management | 7.51 % | |
Nausea/vomiting/dehydration | 6.02 % | |
Gastrointestinal tract | 5.64 % | |
10 year risk for distant recurrence without chemotherapy | ||
Adjuvant! Online low risk | 5.39 % | Paulden et al. (2013) |
21-Gene assay low risk | 2.61 % | |
21-Gene assay int. risk | 3.84 % | |
21-Gene assay high risk | 18.91 % | |
Adjuvant! Online int. risk | 20.36 % | |
21-Gene assay low risk | 4.24 % | |
21-Gene assay int. risk | 14.90 % | |
21-Gene assay high risk | 44.23 % | |
Adjuvant! Online high risk | 24.12 % | |
21-Gene assay low risk | 4.24 % | |
21-Gene assay int. risk | 14.90 % | |
21-Gene assay high risk | 44.23 % | |
10 year risk for distant recurrence with chemotherapy | ||
Adjuvant! Online low risk | 5.68 % | Paulden et al. (2013) |
21-Gene assay low risk | 4.98 % | |
21-Gene assay int. risk | 5.62 % | |
21-Gene assay high risk | 8.58 % | |
Adjuvant! Online int. risk | 7.35 % | |
21-Gene assay low risk | 5.79 % | |
21-Gene assay int. risk | 8.18 % | |
21-Gene assay high risk | 8.91 % | |
Adjuvant! Online high risk | 7.68 % | |
21-Gene assay low risk | 5.79 % | |
21-Gene assay int. risk | 8.18 % | |
21-Gene assay high risk | 8.91 % | |
Risk of mortality due to toxicity from chemotherapy | 0.1 % | Medical University Innsbruck (2012) |
Median life expectancy following distant recurrence (months) | 25.8 | Medical University Innsbruck (2012) |
Risk of mortality due to other causes | Life table | Statistik Austria (2012) |
Costs (inflated to 2011 Euros) | ||
21-Gene assay | 3180 | Jahn, Personnel email-communication with manufacturer (2012, unpublished) |
Costs for chemotherapy | ||
Echocardiography (one time) | 28 | Tilak Financial Department and Cost Data Report (2012) |
Chest radiography (one time) | 23 | |
Port implantation (one time) | 550 | |
Laboratory test (per cycle of chemotherapy) | 46.5 | |
Blood panel (per week for 6 months) | 3.75 | |
Human resources (per cycle of chemotherapy) | 48 | |
Hospitalization (3 days) | 620 | |
Total additional costs for chemotherapy (6 months) | 2,089.5 | |
Total costs for FEC (Fluorouracil 500 mg/m2, Cyclophospamid 600 mg/m2, Epirubicin 90 mg/m2) | 672.16 | |
Total costs for DOC (Docetaxel 75 mg/m2) | 1042.5 | |
Pegfilgrastim 6 mg | 1175.57 | |
Tropisetron-Hydrochlorid 5 mg 5 pills | 85.90 | |
Total costs for chemotherapy (Additional costs, FEC, DOC, Pegfilgrastim, Tropisetron-Hydrochlorid, 6 months) | 11,372.96 | Derived from Tilak Financial Department and Cost Data Report (2012); Medical University Innsbruck (2012) |
Follow up costs for the first 5 years after chemo therapy (costs per month/treatment) | ||
Anastozol 1 mg | 73.7 | Tilak Financial Department and Cost Data Report (2012) |
Lertozolum 2.5 mg | 101.2 | |
Exemestanum 25 mg | 75.87 | |
Other treatment costs for the first 5 years after chemo | 5016.8 | Derived from Tilak Financial Department and Cost Data Report (2012); Medical University Innsbruck (2012) |
Mammography | 32 | Tilak Financial Department and Cost Data Report (2012) |
Examination | 85.5 | |
Follow up costs for the first 5 years after chemo per month | 21.54 | Derived from Tilak Financial Department and Cost Data Report (2012); Medical University Innsbruck (2012) |
Follow up Costs after the first 5 years after chemo therapy (costs per month/treatment) | ||
Follow up costs per month | 9.79 | Derived from Tilak Financial Department and Cost Data Report (2012); Medical University Innsbruck (2012) |
Costs of diagnosing distant recurrence | ||
Total costs of diagnosis of distant recurrence | 248.5 | Derived from Tilak Financial Department and Cost Data Report (2012); Medical University Innsbruck (2012) |
Costs of treating distant recurrence | ||
Total costs per 25.8 months | 32,015.26 | Tilak Financial Department and Cost Data Report (2012) |
Treatment of non-fatal chemotherapy toxicity | ||
Neutropenia/fever/infections | 5231.46 | Ontario Case Costing Initiative (2011); Medical University Innsbruck (2012) |
Pain management | 3270.66 | |
Nausea/vomiting/dehydration | 3173.45 | |
Gastrointestinal tract | 5169.31 | |
Treatment of fatal toxicity | 36,260 | Walter (2012) |
Utility weights | ||
First year following diagnosis (while on hormone therapy) | 0.744 | Lidgren et al. (2007) |
First year following diagnosis (while on chemotherapy) | 0.620 | |
Second and following years prior to distant recurrence | 0.779 | |
Following distant recurrence | 0.685 | |
Dead | 0 |